Chong Kun Dang Pharmaceutical operating profit up 15% on Japanese basis; sales edge up slightly
Predicted impact: Low
Same Q3 operating profit rise of about 15% already reported in last 14 days.
Chong Kun Dang Pharmaceutical종근당
185750 · KOSPI · ₩185750 · 종근당
₩63,100▲ ₩600 (0.96%)End-of-day · Oct 30, 2026 · End-of-day prices.
Chong Kun Dang boosts Q3 operating profit 15% on big pharma products
Predicted impact: Low
Q3 operating profit up 15.4%, a modest gain already reported; lowered one level.
"Wegovy and Eylea effect"…Chong Kun Dang's Q3 operating profit up 15.4%
Predicted impact: Low
Q3 operating profit up 15.4%, already flagged in preliminary earnings; small move expected.
Chong Kun Dang Pharmaceutical's third-quarter operating profit rises 15% year on year, improving profitability on top-line growth
Predicted impact: Low
Q3 operating profit up 15.4% is modest and already flagged as preliminary earnings.
Chong Kun Dang Pharmaceutical: Q3 operating profit ₩23.7B, up 15.4% year on year
Predicted impact: Low
Q3 profit up 15.4%, modest and preliminary results already reported.
Chong Kun Dang Pharmaceutical highlights 'Benfobel S' with enhanced peripheral nerve and liver function improving ingredients
Predicted impact: Low
Drug product highlight; no size of sales or deal given.
종근당건강 아임비타, 월드비전과 취약계층 청소년 영양 관리 지원
Predicted impact: Low
Social responsibility and small product awards; no material size.
Chong Kun Dang targets foreign tourists with skin disease medicines
Predicted impact: Low
Same foreign-tourist skin medicine push; the K-Pharmacy recommendation was already reported in the last 14 days.
Chong Kun Dang pharmaceutical targets Japan-bound visitors with skin medicine
Predicted impact: Low
Skin medicine marketing to tourists; the K-Pharmacy recommendation was already reported in the last 14 days.
Chong Kun Dang Pharmaceutical's Aimvita wins food category grand prize at the 2026 Korea SNS Awards
Predicted impact: Low
Consumer product award; marketing recognition with no financial size.
종근당 '더마그램 피디알엔' 관광공사 추천템 선정
Predicted impact: Low
Chong Kun Dang's 'Dermagram PDRN Cream' selected as a recommended product for Korea Tourism Organization's K-Pharmacy shopping
Predicted impact: Low
Customized Rehabilitation Plus Specialized Nursing: Chong Kun Dang Industry Opens Premium Nursing Home in Yongin
Predicted impact: Low
Opening of a nursing home; small and routine for a company this size.
Chong Kun Dang Pharmaceutical Industry Opens Premium Elderly Care Facility, Strengthens Individual Rehabilitation in Southern Greater Capital Area
Predicted impact: Low
Same nursing facility opening already covered in the last 14 days.
Chong Kun Dang's 'Vempevel S' strengthens ingredients for improving peripheral neuropathy and liver function
Predicted impact: Low
Routine drug ingredient update for an existing product line.
종근당건강, ‘눈 노화·눈 건조’ 한 번에 잡는 '아이클리어 올인원' 출시
Predicted impact: Low· Actual: −7.0% vs sector, volume 1.3× normal (5 trading days)
Consumer eye-health supplement launch; same iClear product already reported in last 14 days, so lowered.
Chong Kun Dang Health's iClear launches 'iClear All-in-One', applying Korea's first combined eye-aging and dryness functional ingredient
Predicted impact: Low· Actual: −5.1% vs sector, volume 1.3× normal (5 trading days)
Consumer health product launch; small revenue impact.
Also known as: Chong Kun Dang Pharmaceutical / 종근당 / 185750 / KRX:185750
Source: KRX statistical information